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Parkinson’s disease (PD), the second most common neurodegenerative movement disorder, 
affects approximately 2% of the population over 65. At present, there is only symptomatic but no 
causal cure for PD. Mitochondria are double membrane-bound organelles that are essential for energy 
production and cellular homeostasis in eukaryotic cells. Defects in this organelle are the underlying 
cause of several neurological disorders, namely PD. This mitochondrial connection has been furthered 
strengthened by the identification of mutations in the PINK1 gene that are linked to early-onset 
recessive PD. PINK1, a mitochondria targeted Ser/Thr kinase, regulates ATP production in healthy 
mitochondria by phosphorylating Complex I of the Electron Transport Chain. However, in damaged 
mitochondria PINK1 will phosphorylate Parkin and signal mitochondria for clearance via mitophagy. 
While understanding the regulation of PINK1 activity is pivotal to interpret how PINK1 executes its 
different functions in both healthy and damaged mitochondria it still remains unclear how PINK1 
induced loss-of-function can affect the kinase activity and the overall (auto)phosphorylation status of 
PINK1.  
 To scrutinize the impact that the PINK1 clinical mutation have on PINK1 function, we 
systematically analysed five PD-causing clinical mutations G309D, L347P, E417G, H271Q and 
W437X. In order access their ability to phosphorylate the known PINK1 substrate Parkin and to 
(auto)phosphorylate PINK1 an in vitro phosphorylation assay was implemented. To determine their 
effect towards Parkin recruitment and sequential induction of mitophagy an immunofluorescence 
techniques was used where staining against Parkin and a mitochondria reside protein was performed. 
  Our results indicate that PINK1 is essential for Parkin recruitment, however the kinase activity 
is not required for this Parkin-mediated mitophagy pathway. 
 






A doença de Parkinson (DP), é a segunda doença neurodegenerativa mais comum, afetando 
aproximadamente 2% da população acima dos 65 anos. Actualmente, o único tratamento que existe é 
sintomático. As mitocôndrias são organelos com duas membranas, essenciais para a produção de 
energia e homeostase celular nas células eucarióticas. Defeitos nestes organelos estão 
aproximadamente 1% da população acima dos 65 anos. Actualmente, não existe nenhuma mas apenas 
existe um tratamento sintomático. As mitocôndrias são organelos com duas membranas, essenciais 
para a produção de energia e homeostase celular nas células eucarióticas. Defeitos nestes organelos 
estão na base de diversas doenças neurológicas, nomeadamente na DP. Esta conexão com a 
mitocôndria foi reforçada com a identificação de mutações no gene PINK1 associadas à forma juvenil 
recessiva de DP. PINK1 é uma cinase Ser/The que regula a produção de ATP numa mitocôndria 
saudável, através da fosforilação do complexo I da cadeia de transporte de electrões. No entanto, em 
mitocôndrias danificadas, a PINK1 fosforila a Parkin sinalizando a mitocôndria para degradação, 
através de um processo chamado mitofagia. Desta forma, a compreensão da regulação da actividade da 
PINK1 é essencial para a interpretação de como esta proteína executa as suas diferentes funções, tanto 
na mitocôndria saudável como na danificada. Ainda existem dúvidas sobre como é que a perda de 
função por parte da PINK1 afecta a actividade de cinase e, consequentemente a (auto)fosfoforilação. 
De forma a clarificar o impacto de mutações na função da PINK1, foram analisadas cinco 
mutações clínicas, G309D, L347P, E417G, H271Q e W437X, que culminam em DP. Para aceder à sua 
capacidade de fosforilar Parkin, já conhecido substrato da PINK1, assim como a própria 
autofosforilação desta, foi implementado um ensaio in vitro. Adicionalmente, para determinar o 
potencial efeito destas mutações no recrutamento da Parkin e posterior indução da mitofagia, recorreu-
se a técnicas de imunofluorescência, utilizando marcação para ambas, Parkin e uma proteína 
mitocondrial endógena.  
Os nossos resultados sugerem que PINK1 é necessária para o recrutamento da Parkin, mas a 
sua actividade de cinase não é imprescindível para a via de degradação mediada pela Parkin. 
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1. General Introduction 
 
Parkinson’s Disease 
In 1817 James Parkinson describes the disorder that bears his name, publishing as “An Essay on 
the Shaking Palsy”. At the time, he dubbed the disorder as “Shaking Palsy”, once he observed what he 
thought that might be a neurological illness, consisting of resting tremor and a peculiar form of 
progressive motor disability, attending the signs and symptoms seen in six individual, three of whom 
were merely seen on London’s streets (Parkinson, 2002). Later that century, these symptoms, 
including bradykinesia, muscular rigidity, resting tremor and postural and gait impairment, were 
refined by Jean-Martin Charcot (Charcot 1872). 
Currently Parkinson’s Disease (PD) is a known progressive multifactorial neurodegenerative 
disorder, characterized by the preferential loss of dopaminergic neurons in the region of the brain 
known as the substantia nigra, the disease’s pathological feature. Importantly, neurodegeneration is 
not limited to the substantia nigra, the ventrolateral tier brain region which contains neurons that 
project to the dorsal putamen of the striatum is also strongly affected with disease progression, 
resulting in movement symptoms (Figure 1.1) (Farrer, 2006; Kalia & Lang, 2015). Clinical symptoms 
only appear when loss of dopaminergic neurons of the substancia nigra pars compact (SNpc DA) is  
approximately 50-70% (Orth & Schapira, 2002; Chinta & Andersen, 2008).  
Neurodegeneration causes an imbalance of excitatory (acetylcholine) and inhibitory (dopamine) 
neurotransmitters and, it’s believed that lesions in this specific area leads to the characteristic motoric 
symptoms of PD (reviewed in Kalia & Lang, 2015). Pathologically, a second hallmark is fibrillary α-
synuclein intracellular inclusions, where the insoluble α-synuclein aggregates form inclusion bodies 
within the cell body (Lewy bodies) and processes (Lewy neurites) of neurons (reviewed in Capriotti & 
Terzakis, 2016).  
PD affects approximately 2% of adults over the age of 65 and 4% of adults over the age of 80, 
which makes it one of the most common neurodegenerative disorders, second in prevalence to 
Alzheimer disease (Kalia & Lang, 2015; Capriotti & Terzakis, 2016). In an aging population where 
life expectancy is rising, this occurrence should rise by more than 50% by 2030 (Kalia & Lang, 2015). 
This raising in prevalence has been motivating the investigation around this disease as it is still 
unknown what triggers its initiation. However, the cause presumably is a combination of genetic and 
environmental factors where age is the most consistent risk factor (Capriotti & Terzakis, 2016). 










Presently, there is no cure for PD, the only existing treatment is symptomatic (Samii et al., 2004; 
Capriotti & Terzakis, 2016). The most common pharmacologic treatment used is levodopa, since it 
provides the greatest symptomatic help, but it losses it effectiveness due to habituation. Another 
therapeutic options includes surgical options, from deep-brain stimulation to restorative treatment, but 
negative results have dampened enthusiasm in these approaches (Samii et al., 2004; Capriotti & 
Terzakis, 2016). There has also been some substances describe as potential neuroprotective agents, 
such as Vitamin E, selegiline and coenzyme Q10, but no irrefutable evidences exists (Samii et al., 
2004). 
 
Mitochondria and PD  
The etiopathogenesis of sporadic cases is complex, but it is believed that genetic susceptibility and 
environmental factors contributes to this disease progression and both influence various mitochondrial 
aspects, such as bioenergetics, quality control, dynamics and transport (Moon & Paek, 2015). It is well 
known that aberrant mitochondrial forms and functions are connected with idiopathic (or sporadic) 
and familial PD (Henchcliffe & Beal, 2008). However, the mechanism still remains to be clarified. 
Mitochondrial dysfunctions are mainly characterized by the generation of reactive oxygen species 
(ROS), a decrease in the electron transport chain (ETC) Complex I activity, ATP depletion and 
cleaved caspase-3 activation (reviewed in  Moon & Paek, 2015).  
There is increasing evidence that link Complex I function to PD. Complex I is the first complex of 
the multimeric enzymatic system of the ETC, whose overall function is the generation of ATP.  
Figure 1.1 - The main brain regions affected in 
Parkinson disease. Represented is a lateral brain’s 
section, with the anterior to the left. The yellow 
areas are affected in PD (Farrer, 2006) 
-3- 
The role of mitochondria in PD became evident when it was discovered that the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) metabolite, MPP
+ 
(N-methyl-4-phenylpyridinium) inhibits 
Complex I of the ETC leading to DA loss in a way very similar to PD. After MPTP enters the cells 
through monoamine transporters, MPP
+
 binds and inhibits NADH CoQ10 reductase, decreasing ATP 
synthesis and increasing generation of free radicals (Orth & Schapira, 2002; Pesah et al., 2004). 
Besides MPTP, rotenone also inhibits the Complex I by binding to the Complex I subunit ND-1 
protein and leading to increased ROS levels. Rotenone induces a Parkinsonism syndrome in animal 
models and also in humans (Narendra, Tanaka, Suen, & Youle, 2008;  Schapira et al., 1990). Another 
poisonous reagent is paraquat, whose toxicity is executed in a similar fashion as MPP
+
, causing 
generation of free radicals and oxidative stress (Schapira et al., 1990; Berry et al., 2010). 
It is also worth noting that the brain consumes 20% of total resting body energy,  therefore with 
such a high demand in mitochondria driven ATP production it is not surprising that hampered 
mitochondria will lead to a diseased brain (Orth & Schapira, 2002; MacAskill & Kittler, 2010). 
Further,  SNpc DA have been characterized as a highly energy demanding population of neurons, thus 
it should be expected an increased mitochondria biogenesis, as well as increased basal oxidative 
phosphorylation (Henchcliffe & Beal, 2008). This feature must be due to the metabolic sustaining of 
their enormous axonal arborization, demonstrated by Pacelli et al., 2015. It was also shown that 
mitochondrial reactive oxygen species (mROS) production is higher in these neurons due to the 
dopamine oxidative metabolism. Further, antioxidants such as reduced glutathione, are weakly 
synthesized in SNpc DA (Chinta & Andersen, 2008). This bioenergetics and morphological 
characteristics make SNpc DA more vulnerable to mitochondrial dysfunctions.  
 
Then, what makes Mitochondria so special?  
Known as the energy powerhouse of the cell, Mitochondria are double membrane organelles that 
have 4 distinct sub-mitochondrial compartments: the outer mitochondrial membrane (OMM), the 
intermembrane space (IMS), the inner mitochondrial membrane (IMM), and the matrix. The 
compartmentalization is crucial for vital mitochondrial functions. They actively sustain a highly 
negative potential across their inner membrane (ΔΨ) that is maintained by four protein complexes I, II, 
III and IV of the mitochondrial ETC, that together with the F0/F1-ATP-synthase (Complex V), 
constitute the oxidative phosphorylation (OXPHOS) system. Maintenance of a highly negative 
potential across their inner membrane (ΔΨ) is essential for mitochondrial function and cell viability 
(Schapira, 2010).  
Mitochondria are semi-autonomous since they contains their own DNA (mtDNA), a double 
stranded 16.6-kb circular molecule consisting of a heavy (H) and a light (L) chain, without any histone 
-4- 
coating. The mtDNA encodes 13 proteins, 2 ribosomal RNAs and 22 transfer RNAs. The mtDNA has 
some particularities: it is only inherited from the mother; exists approximately 8-10 mtDNA’s per 
mitochondrion, varying in different tissues; and the 13 proteins translated are all components of the 
ETC. Even having their own DNA, an overwhelming number of nuclear encoded proteins are targeted 
to the mitochondria, such as replication, transcription, translation and repair proteins (Orth & 
Schapira, 2002; Palikaras & Tavernarakis, 2014). The mtDNA does not have a complete repertoire of 
repair mechanisms to eliminate mutated DNA sequences, making it therefore rather vulnerable to 
mutations that accumulate with aging (Orth & Schapira, 2002). To prevent and reduce potential 
mitochondrial stress generators, these organelles have a mitochondrial unfolded protein response 
(UPR
mt
) system that deals with the accumulation of misfolded and toxic proteins (Moon & Paek, 
2015). The UPR
mt
 is composed by controlling chaperones and transcriptional proteases (Roberts et al., 
2016). In addition, evidences suggest that vesicles derived from mitochondria engulf selected 
mitochondrial cargos and deliver them to peroxisomes for degradation.  At the same time anti-oxidant 
pathways are activated, for example mitochondrial superoxide dismutase and glutathione (Roberts et 
al., 2016). In addition to these processes, mitochondria are able to regulate their internal quality by 
two processes: one that allows degradation of OMM proteins through the ubiquitin-proteasome 
system; and another one that uses the autophagy-lysosome pathway for elimination of mitochondria as 
whole organelles, known as mitophagy (Palikaras & Tavernarakis, 2014; Scarffe et al., 2014; Eiyama 
& Okamoto, 2015) 
Mitochondria have an important role in cellular processes by supporting cellular metabolic events, 
as iron-sulfur cluster biogenesis, amino acid synthesis and lipid metabolism. In order to maintain 
cellular homeostasis, mitochondria are able to regulate the calcium influx and inhibit apoptosis. Some 
of these cellular reactions may lead to oxidative stress with ROS formation, as superoxide anions, 
hydroxyl radical and hydrogen peroxide (Orth & Schapira, 2002). Mitochondria are fueled by 
pyruvate and fatty acids, which are used as carbon sources for the tricarboxylic acid cycle (or Krebs 
cycle) in the mitochondrial matrix. 
The aim of mitochondrial quality control is the maintenance of a healthy pool of mitochondria 
within the cell. This term is used to describe the coordination of mitochondrial dynamics, biogenesis 
and mitophagy (Scarffe et al., 2014). Mitophagy is a specialized mitochondria autophagy, or more 
specifically  macroautophagy, since it involves sequestration in a double membrane structure called  
autophagosome of mitochondria and selectively triggering them for clearance (Fig. 1.2) (Hattori et al., 
2014; Scarffe et al., 2014). 
Mitochondria can change shape, size and inner membrane organization. All these processes are 
regulated by fusion and fission events. In mammalian cells, mitochondrial fission depends on the 
GTPase dynamin-related protein (Drp1) (Büeler, 2010; Roberts et al., 2016). Dpr1 translocate from 
-5- 
the cytosol and accumulates on OMM, where it oligomerizes into ring-like structures that will 
constrict the mitochondria through GTP hydrolysis, leading to the formation of new “daughter” 
mitochondria. This process is essential in facilitating mitochondrial transport as well as the autophagic 
degradation of damaged mitochondria. On the other hand, fusion depends on the action of 3 GTPases: 
Mitofusins 1 and 2 (Mfn1/2) that are OMM proteins that tether organelles to the membrane for OMM 
fusion; and Optical atrophy 1 (Opa1), an IMM protein that mediates inner membrane fusion (Büeler, 
2010; Roberts et al., 2016). Fusion process is crucial for maintain a functional mitochondrial 
population within a cell, as mitochondria do not function in isolation but rather in a complex extensive 
network, its morphology undergoes continuous changes in response to metabolic stimuli and signaling 




Figure 1.2 - Mitochondrial Quality Control. Mitochondria have different pathways to promote mitochondrial biogenesis 
and dynamics. (A) Proteolytic system; (B) Proteasome system; (C) Transportation to lysosome or peroxisome; (D) 
Fission/Fusion; (E) Mitophagy (Palikaras & Tavernarakis, 2014) 
 
Genetics in PD 
Nowadays, it is accepted that the involvement of mitochondria in PD is not only restricted to a 
decrease in ATP and increase in ROS production arising from the defective function of the respiratory 
chain. Defects in mitochondrial trafficking, dynamics, identification of mutations in genes involved in 
mitochondrial mitophagy) or defects in mitochondrial calcium buffering are emerging as 
mitochondrial dysfunctions related to PD (Aroso et al., 2016). Thus, the regulation of these 
mechanisms is essential to maintain mitochondria healthy. 
The past 15 years were marked by important discoveries which have led to a better understanding 
of the molecular pathogenesis of PD. Although 90% of cases are considered sporadic, the 
identification of genes responsible for familial forms of PD where a clear “mendelian” autosomal 
dominant (where one mutated allele is sufficient to cause the disease) or autosomal recessive pattern 
-6- 
(where two mutated alleles are needed to originate the disease) of inheritance is observed have been 
crucial for a better understanding of the disease (Gasser, 2009; Scarffe et al., 2014; Kalia & Lang, 
2015). 
More than ten genes have been identified, and six of these genes were identified as mediating the 
autosomal dominant forms of PD, being the most common SNCA and LRRK2 (table1.1). The gene 
SNCA encodes the α-synuclein protein, the principal constituent of Lewy bodies (Polymeropoulos et 
al., 1996). So far, reports have identified three different missense mutations, as well as duplications 
and triplications (Klein & Westenberger, 2012). Three missense mutations impair the amino-terminal 
domain of α-synuclein causing misfolding and aggregation of the protein, a feature that is strongly 
correlated with PD (Klein & Westenberger, 2012; Recasens & Dehay, 2014). 
The most frequent cause of autosomal dominant PD are mutations in LRRK2 (Klein & 
Westenberger, 2012). This gene encodes the protein leucine-rich repeat kinase 2 LRRK2, a large 
multidomain enzyme, coupling kinase and GTPase activities with a number of protein/protein 
interaction domains (Paisán-Ruiza et al., 2013). 
Autosomal recessive PD occurs less frequently but occurs in early-onset of the disease. In the 
form the associated genes are Parkin (Kitada et al., 1998), PINK1 (Valente et al., 2004) and DJ-1 
(Bonifati et al., 2003) (table1.1), interesting all implicated  within mitochondria pathways. 
Table 1.1 – Most frequently genes implicated in monogenetic PD. Most frequently genes confirmed to be implicated in 










Parkin, the second largest gene in human genome (Kitada et al., 1998; Klein & Westenberger, 
2012), encodes an E3 ubiquitin ligase that catalyzes the ubiquitination of a range of proteins (Sarraf et 
Gene Mutations Inheritance Gene poduct 
SNCA 











Parkin >100 mutations AR 
Parkin, E3 ubiquitin 
ligase 
PINK1 >50 mutations AR 
PTEN-induced 
kinase 1 
DJ-1 >10 mutations AR Daisuke Junko 1 
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al., 2013), particularly on damaged mitochondria (Narendra et al., 2008). In agreement, mutations in 
this protein appear to lead to mitochondrial dysfunctions (Greene et al., 2003). Pathologically patients 
with these alterations, although lacking α-synuclein aggregates, display clinical features of idiopathic 
(or sporadic) PD (Greene et al., 2003; Pesah et al., 2004). 
PINK1, another autosomal recessive gene, encodes for the a serine/threonine (Ser/Thr) kinase 
PINK1, whose mutations are less common than Parkin (Gasser, 2009). There is a genetic link between 
PINK1 and Parkin as mutant models for both proteins seem to have the same phenotypes, such as 
flight and climbing defects in the Drosophila model (Greene et al., 2003; Clark et al., 2006; Park et 
al., 2006). Together, PINK1 and Parkin regulate mitochondrial quality control via clearance of 
damaged mitochondria (Narendra et al., 2010). 
Mutations in the DJ-1 gene are the least common and its function it is still not well understood 
(Bonifati et al., 2003). The protein encoded is  member of ThiJ/PfpI family and has H2O2 
responsiveness, functioning as a sensor for oxidative stress and is an antioxidant (reviewed in Cheon, 
Chan, Chan, & Kim, 2012). 
 
PINK1 
Encoded by the PARK6 gene in chromosome 1p36, alterations in this protein are the second 
most common cause of early onset autosome recessive PD (Hatano et al., 2004; Bonifati et al., 2005; 
Singleton et al., 2013; Requejo-Aguilar & Bolaños, 2016). Phosphatase and tensin homolog (PTEN)-
induced putative kinase 1 (PINK1) encodes a 581 amino acid protein with an N-terminal 
mitochondrial targeting sequence (MTS) spanning from residues 1-34, a conservative serine/threonine 
kinase domain from residues 150-513 and a C-terminal non catalytic region from residues 541-581 
(Valente et al., 2004; Kondapalli et al., 2012). A hydrophobic patch formed by 11 amino acids   can 
also be found after the MTS. Bioinformatic analysis suggests that residues Gly-193 to Lys-507 form 
the ATP-binding cassette whereas residue Thr-313 is a autophosphorylation regulatory residue (Petit 
et al., 2005).  
PINK1 is ubiquitously expressed in all brain regions and in all cells types. Sporadic cases of 
PD or PD-related clinical mutations do not affect expression levels or localization pattern of PINK1 
(Gandhi et al., 2006). PINK1 has been detected in both cytosol and mitochondria (Valente et al., 2004; 
Beilina et al., 2005; Silvestri et al., 2005; Lin & Kang, 2008). 
Drosophila PINK1 mutants exhibit male sterility, wing postural instability with rigidity that 
lead to locomotion difficulties, flight muscle degeneration, mitochondrial impairment, low ATP levels 
and apoptosis (Clark et al., 2006; Park et al., 2006; Scarffe et al., 2014). Studies showed that PINK1 
-8- 
kinase is essential for maintaining mitochondrial integrity and functions in vivo, as well as to dictate 
Parkin localization through direct phosphorylation (Kim et al., 2008). PINK1 knockout mouse or 
human dopaminergic neurons besides showing a high sensitivity to apoptosis also have abnormalities 
in mitochondrial morphology, a reduced membrane potential, and an increased ROS generation 
(Morais et al., 2009; Moon & Paek, 2015; Pacelli et al., 2015) 
 
In healthy mitochondria, PINK1 is guided into mitochondria through the mitochondrial import 
machinery translocase of the outer membrane (TOM) and of the inner membrane (TIM) complexes, in 
a mitochondrial membrane potential dependent manner (Fig.1.3). PINK1 is translocated, partially, 
through TOM and TIM exposing the positively charged MTS to the matrix, which is removed by 
mitochondrial processing peptidase (MPP), and then cleaved by the inner mitochondrial membrane 
protease presenilin-associated rhomboid like protease (PARL) (Nguyen et al., 2016). Thus, in cells 
normal conditions, three forms of PINK1 protein are detected: the full-length form (63 kDa) and two 
cleaved forms one form at approximately 55kDa that represents an intermediate PINK1 species 
produced by the inner mitochondrial membrane protease presenilin-associated rhomboid like protease 
(PARL); and 45kDa form cleaved by MPP‐mediated cleavage, between aminoacids Alanine 103 
(Ala103) and Phenylalanine 104 (Phe104) (Deas et al., 2011; Meissner et al., 2011) and then 
translocated to the cytosol where it is rapidly degraded through N-end rule pathway (Greene et al., 
2012; Song et al., 2013; Yamano & Youle, 2013; Voigt et al., 2016).  
Complex I of the ETC is pivotal in generating the electrochemical gradient across IMM. 
Compromised Complex I activity has been related with PD sporadic cases (Schapira et al., 1990) and 
further corroborated in PINK1 null mice (Morais et al., 2009). Vilain and co-workers suggested a 
connection between PINK1 and Complex I where PINK1 is acting with or in parallel with Complex I 
(Vilain et al., 2012). The yeast Complex I Ndi1p rescued several phenotypes observed in Drosophila 
PINK1 mutants further strengthening Complex I deficiency as the underlining cause of PINK1 related 
phenotypes. Later, Morais et al., 2014 showed that PINK1 regulates Complex I function by 




Figure 1.3 - PINK1 processing in healthy mitochondria; firstly PINK1 is imported into OMM through TOM, and then 
IMM over TIM, where it is processed by MPP and PARL, exposing N-end rule substrate cytosolic and promoting PINK1 
degradation (adapted from Nguyen, Padman, & Lazarou, 2016). 
 
When mitochondria are depolarized, import of PINK1 within the mitochondria is inhibited and 
PINK1 is stabilized on the mitochondrial outer membrane triggering the damaged mitochondria for 
clearance via aPINK1/Parkin mediated mitophagy pathway (Narendra et al., 2010; Seirafi et al., 
2015). PINK1initiates mitophagy by phosphorylating Ubiquitin (Koyano et al., 2014), Mitofusin 2 
(Chen & Dorn, 2013) and Parkin (Clark et al., 2006; Park et al., 2006; Matsuda et al., 2010). For this, 




 (Okatsu et al., 
2012; Aerts et al., 2015). 
Approximately 50 pathogenic PINK1 mutations were identified; being that large amount of 
them located within the kinase domain, suggesting that this kinase activity plays a crucial role in the 
PD pathogenesis (Fig.1.4) (Rogaeva et al., 2004; Bonifati et al., 2005; Criscuolo et al., 2006; Kawajiri 
et al., 2011). These homozygous point mutations R246X, H271Q, E417G and L347P, involving exons 
3, 4, 5 and 6, and two nonsense mutations Q239X and R492X were identified in Asian families 
(Hatano et al., 2004). The residues implicated in H271Q, E417G and L347P mutations appear to be 
highly preserved between PINK1 homologs (Hatano et al., 2004). Two missense mutations (E420K 
and L489P) were described to abrogate PINK1 protective effect against cell death (Petit et al., 2005). 
All patients shown early age onset, long disease duration and good response to L-dopa, therefore there 
does not exist any clinical features that will distinguish PINK1 mutations from Parkin or DJ-1 
mutations. Atypical clinical features have been observed including psychiatric disturbances, dystonia 
at onset and sleep benefit (Hatano et al., 2004; Valente et al., 2004). 
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PINK1 is  known to be included in numerous pathways, and to interact with several substrates 
related to mitochondrial homeostasis and mitochondrial quality control (Table 1.2) (Gómez-Sánchez et 
al., 2016). PINK1 is also responsible for blocking the activation of apoptotic signalling pathways by 
reducing caspase-3 activity and Cytochrome c translocation (Petit et al., 2005). Other studies have also 
shown that PINK1 prevents the transport of defective mitochondria along microtubules by 
phosphorylating Miro (Weihofen et al., 2009). 
 
PINK1 is pivotal in promoting cell survival by interacting with a mitochondrial molecular 
chaperone that protects against oxidative-stress-induced apoptosis, TNF receptor-associated protein 1 
(TRAP1) (Pridgeon et al., 2007). The clinical PINK1 mutants G309D and L347P were unable to 
phosphorylate TRAP1, in contrast with W437X clinical mutations where no difference was observed 
when compared to WT PINK1. These results suggest that cell survival may be affected by PINK1 
function, especially in the case of the G309D and L347P clinical mutants.   
It was also shown that kinase activity of PINK1 is involved in the regulation of mitochondrial 
apoptotic pathway, as its depletion increases cells susceptibility to oxidative stress induced apoptosis 
(Pridgeon et al., 2007). It is conceivable to assume that alterations in this domain may lead to 
dysfunctions in kinase activity of this protein, and indeed L347P mutations appears to lead to a protein 
instability (Beilina et al., 2005). But studies about this possible dysfunction have been a little 
controversial. In some studies the in vitro phosphorylation assay were performed with hPINK1 
orthologues instead, such as Tribolium castaneum TcPINK1, that is remarkably more active than 
hPINK1(Woodroof et al., 2011). Recently, it was shown that different PINK1 orthologues have 
different substrate selectivity, so the extrapolation of obtained results back to human scenario need to 
be performed with caution (Aerts et al., 2016). 
 
Table 1.2 – Resume of PINK1 Substrates mentioned. Besides (auto)phosphorylates itself, PINK1 as another substrates that 
allows it to control pathways as mitophagy, mitochondrial motility and oxidative phosphorylation (OXPHOS).  Only Miro, 
Figure 1.4 – Localization of PINK1 mutations in monogenic PD patients. More than 50 
mutations have already been identifies; MTS = Mitochondrial Targetting Sequence, TM = 
Transmembrane Domain (Pickrell & Youle, 2015). 
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TRAP1, Parkin and Ubiquitin are described as directly phosphorylated by human PINK1 (MOM, mitochondrial outer 
membrane; MIM, mitochondrial inner membrane; IMS, intermembrane space). 
Substrate Localization Function 
Miro MOM Mitochondrial motility 
Mitofusin 2 MOM Mitophagy 
NDUFA10 MIM OXPHOS 
Parkin Cytosol/MOM Mitophagy 
TRAP1 IMS/MIM Stress response 




Mutations in the PARK2 gene, also known as 
Parkin, are the most common cause of autosomal 
recessive PD. The gene encodes a 465-amino acid E3 
ubiquitin ligase, member of the RING1-in Between-
RING-RING2 (RBR) family of E3’s, capable of 
mediating mono or poli-ubiquitination (Scarffe et al., 
2014; Koyano & Matsuda, 2015; Roberts et al., 2016). 
An E3 ubiquitin-protein ligase, ubiquitinates proteins and 
labels them for degradation. Ubiquitination consists of a 
76 amino acid polypeptide covalently conjugated to a 
lysine residue or N-terminal amino group of a substrate 
protein allowing 3 enzymes to act sequentially: ubiquitin-activating enzyme (E1), ubiquitin-
conjugating enzyme (E2) and ubiquitin-protein ligase (E3) (Seirafi et al., 2015; Chin & Li, 2016). 
The protein structure of Parkin is formed by the following independent domains (Fig.1.5): N-
terminal ubiquitin-like (Ubl), four zinc-binding RING0, RING1, IBR (in-between RING), repressor 
element of Parkin (REP) and an N-terminal RING2 domain. The Ubl domain is involved in substrate 
recognition, binding SH3 and ubiquitin interacting motif (UIM) domains, proteasome association, and 
regulation of cellular Parkin levels and activity (Trempe, 2014; Koyano & Matsuda, 2015; Seirafi et 
al., 2015). The IBR domain is attached through a flexible linker (Trempe, 2014). REP domain in line 
with the catalytic center, is important in regulation of Parkin activity, once it is blocking E2 binding 
site on RING1 (Trempe, 2014; Seirafi et al., 2015).  
Figure 1.5 - Parkin’s structure; 4 domains: 
ubiquitin-like (Ubl), four zinc-binding RING0, 
RING1, IBR (in-between RING), repressor element 
of Parkin (REP) and an N-terminal RING2 domain. 
Catalytic Site (Cys431) and Phospho-site (Ser65 ) 
(Seirafi, M. et al. 2015). 
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Parkin is a cytosolic protein, not only expressed in substantia nigra and others brain regions, but 
also in many tissues, including heart, testis and skeletal muscle (Kitada et al., 1998). Results obtained 
from the crystal structure, reveal that under basal conditions, Parkin exists as an autoinhibited form 
(Trempe, 2014).  The catalytic active center, which accepts ubiquitin from E2 and transfers it onto 
substrates of Parkin is residue Cys 431 that lies in RING2 domain and beneath RING0 domain. This 
cysteine forms a thioester bond with ubiquitin, which is then transferred to the lysine residue of the 
substrate via an acyl transfer reaction (Koyano & Matsuda, 2015; Seirafi et al., 2015; Wauer et al., 
2015). The phosphorylation site is between IBR and RING2 domains, close to REP, in the 
autoinhibited conformation (Seirafi et al., 2015) (Fig.1.6). 
Presumably, for Parkin activation it is needed some alterations that make both catalytic center and 
phosphorylation sites available. Reports have demonstrated that ubiquitin is necessary for Parkin 
activation, as it unlocks repression of the Cys 431 leading to destabilization of the Ubl domain and 
RBR core interactions (Koyano et al., 2014; Wauer et al., 2015).Structural analysis suggests a 
conformational flexibility around Ser
65
, so after interaction with PINK1, the Ubl domain may undergo 
conformational changes, enabling PINK1 access (Kondapalli et al., 2012) (Fig .1.6). 
Once activated, Parkin ubiquitinates several mitochondrial proteins that are involved in numerous 
mitochondrial dependent processes, such as mitochondrial motility, fission and fusion (FIS1; OPA1; 
MIRO, Mitofusins), small molecule transport (VDACs); apoptosis (MLC1 and BAX), mitochondrial 
autophagy (p62); and protein translocation (TOMM70) (Sarraf et al., 2013; Scarffe et al., 2014; Seirafi 
et al., 2015). 
Drosophila Parkin mutants show locomotor defects namely in flight and climbing due to 
muscle degeneration; defects in spermatogenesis culminating in male sterility; female infertility most 
probably owing to functional or behavioral functions; fragmentation of mitochondrial cristae; and a 
reduced longevity and body size at eclosion, indicating defects of the growth and proliferating cell 
mechanisms (Greene et al., 2003; Pesah et al., 2004; Clark et al., 2006; Park et al., 2006). 
As Parkin and PINK1 mutants have similar phenotypes one could suspect that they work in 
parallel genetic pathways or that one is able to regulate the other. Studies have revealed  (Clark et al., 
2006; Park et al., 2006) that when Parkin is overexpressed the PINK1 null phenotype is restored. 
However, PINK1 overexpression has no effect on Parkin-null phenotypes. Thus, these studies suggest 
that both proteins function in a common genetic pathway, with PINK1 acting upstream of Parkin. And 
also, PINK1 accumulation is independent on Parkin function as PINK1 accumulates in equal amounts 
in the absence or presence of Parkin (Narendra et al., 2010).  
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Figure 1.6 –Model of Parkin Activation. In the cytosol, Parkin exists in a “closed” conformation, with RING0, Ubl and 
REP, are obstructing, RING2 and E2 binding to RING1, respectively. Parkin is translocated to OMM thanks to the high 
affinity S65-phosphorylated ubiquitin. Because of this interaction, RING1 and IBR originates a displacement of the inhibitory 
UBL and REP, and consequently Parkin structure to open. In the open conformation, E2 charged enzymes are able to bind to 
RING1 domain and expose RING2 catalytic cysteine to participate in ubiquitination; also, PINK1 is able to phosphorylate at 
S65 (Wauer, T. et al. 2015) 
Parkin is selectively recruited to Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) treated 
depolarized mitochondria, and stimulates the autophagic removal of damaged mitochondria (Matsuda 
et al., 2010; Koyano & Matsuda, 2015). Parkin mutated in the Ubl domain leads to a moderate loss in 
mitophagy activity, while mutations in RBR conserved cysteines results in loss of RING2, exhibits a 
severe mitophagy defect; when the whole Ubl domain is truncated Parkin is also inhibited (Narendra 
et al., 2010; Wauer et al., 2015).  
Parkin is involved in the proteasome degradation of several substrates, prevents cytochrome c 
release and α-synuclein aggregation, its loss of function causes accumulation of potentially toxic 
protein aggregates eventually involved in PD, since their role in protecting mitochondria is defected 
(Requejo-Aguilar & Bolaños, 2016). 
 
PINK1/Parkin pathway 
When mitochondria become depolarized, PINK1 accumulates stably on the OMM, due to 




(Okatsu et al., 2012; Aerts et al., 2015). Then, PINK1 phosphorylates Parkin at Ser
65
, a highly 
conserved residue within Ubl domain, leading to Parkin E3 ligase activity (Narendra et al., 2008, 
2010; Kondapalli et al., 2012; Kazlauskaite et al., 2014), and PINK1 also phosphorylates ubiquitin 
(Koyano et al., 2014).  
PINK1-phosphorylated ubiquitin recruits receptors for mitophagy, such as OPTN and NDP52, 
Parkin ubiquitination of mitochondrial substrates, generating ubiquitin chains, amplifies this signal, 
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and recruit ULK1, DFCP1, WIPI1 and LC3 autophagy receptors (Lazarou et al., 2015; Seirafi et al., 
2015). OMM-bound PINK1 also mediates the recruitment of the autophagic protein p62 by Nrf2 and 
TFEB transcription factors (Ivankovic et al., 2016).  
 This process represents a positive feedback model (Fig1.7), where PINK1 phosphorylates a 
basal level of ubiquitin  and subsequently Parkin is activated, increasing the amount of conjugated 
ubiquitin, which is then phosphorylated by PINK1 to recruit more Parkin, that will then in turn 
ubiquitinate other OMM substrates (Seirafi et al., 2015), namely Mfn1/2 (Gegg et al., 2010) that 












In sum, this mitochondrial quality control allows taking away damaged and superfluous 
mitochondria and does not allow the accumulation of oxidized lipids, proteins and DNA, limiting the 
risk of apoptosis. The disruption of the PINK1/Parkin pathway results in an accumulation of abnormal 
mitochondria and overproduction of reactive oxygen species (ROS). This pathway regulates the 
autophagic degradation of damaged mitochondria, through ubiquitin-proteasome and autophagy 
pathways (Narendra et al., 2008, 2010; Matsuda et al., 2010). 
Figure 1.7 – Model of PINK1/Parkin mitophagy induction; 
PINK1 is barred, accumulates, phosphorylates Ubiquitin and 
Parkin, enhancing mitophagy signal. Then PINK1 recruits 







Both PINK1 and Parkin genes are known to be dysregulated in familiar forms of PD. PINK1 
through phosphorylation of its downstream targets regulates multiple mitochondrial processes like 
dynamics and quality control. This pathway responsible for the specific removal of damaged 
mitochondria depends also on Parkin, a PINK1 substrate.  
Given the importance of these encoded proteins in mitochondrial biology, it will be not 
surprising to find that their dysfunction is associated with damaged mitochondria. 
In fact, some groups have described different levels of Parkin phosphorylation and recruitment 
in the presence of clinical mutant forms of PINK1. However, these results vary depending on the 
PINK1 specie that is used in these studies, making extrapolation of these findings into the disease 
context rather difficult to interpret. 
In this work, we aim to understand how the kinase activity of the human form of PINK1 
harboring PD clinical mutations affect Parkin recruitment and Parkin phosphorylation, as well as the 








The plasmids used were pcDNA 3.1 hPINK1 WT (plasmid expressing human PINK1 wild 
type); pcDNA 3.1 hPINK1 KI (plasmid expressing hPINK1 kinase inactive); pcDNA 3.1 hPINK1 ΔN 
WT (plasmid expressing a truncated form of hPINK1WT lacking the first 113 aminoacids); pcDNA 
3.1 hPINK1 ΔN KI (plasmid expressing a truncated form of hPINK1 KI lacking the first 113 
aminoacids). The cDNA of hPINK1 was also cloned into the pMSCV vector, a vector that has the low 
expressing promotor LTR, leading to near-to-endogenous PINK1 expression. The pGEX-4T-1 vector 
was used for the bacterial expression system. These constructs were previously described (Aerts et al., 
2015). The mutant Kinase Inactive form of human PINK1 consists of two point mutations of the 
residues K219 and D362 to Ala. These residues  were predicted by computer modelling analysis as 
crucial residues of the catalytic pore of the kinase domain in PINK1 (Beilina et al., 2005).  
All materials used in these experiments are described in appendix. 
 
Construction of Clinical PINK1 Mutants 
  
Mutant PINK1 constructs were inserted into 
pcDNA3.1 hPINK1-WT and hPINK1-ΔN using 
QuikChange II XL Site-Directed Mutagenesis 
(Agilent technologies). This technique allows the 
alteration, deletion and insertion of a base pair in our 
coding DNA sequence. In our case we performed 
single point mutations that gave rise to the following 
amino acid change: a glycine to aspartic acid in 
G309D, a leucine to proline for L347P, a glutamic 
acid to glycine in E417G, a histidine to glutamine 
for H271Q; and tryptophan to a STOP codon for 
W437X.  
The protocol consists of a three step procedure (Fig.3.1). Before moving to the first, the 
mutagenic oligonucleotide primers must be designed according to the desired mutation. For their 
design, the QuikChange Primer Design Program available online (at 
Figure 3.1 - Schematic representation of the  QuikChange  
Site-Directed Mutagenesis protocol 
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www.agilent.com/genomics/qcpd) was used, where the melting temperatures, that should be ≥78°C, 
are calculated with the following equation: . In addition primers should 
be between 25 to 45 bases in length, with the desired mutation in the middle, a minimum GC content 
of 40% and end with a C or G bases. Primers obtained are described in table 3.1.  
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 First step is the Polymerase Chain Reaction (PCR) that is initiated by adding the following 
components into a PCR tube: reaction buffer (appropriate for the polymerase used), dNTP mix, 
QuikSolution reagent, milliQ water, pcDNA 3.1 hPINK1 ΔN WT, primers forward and reverse for 
each mutation and Pfu Turbo polymerase. To guarantee the kit’s effectiveness and absence of 
contamination from any PCR reaction components, two control samples were used, one provided with 
the kit that consists in a control plasmid, and another one without the template pcDNA 3.1 hPINK1 
ΔN WT, respectively. Reactions were performed with the cycling parameters mentioned in table 3.2. 
   
Table 3.2 - Cycling parameters used for pcDNA 3.1 hPINK1 WT and ΔN mutagenesis reaction 
Cycles Temperature Time 
1 95°C 1 minute 
18 
95°C 50 seconds 
60°C 50 seconds 
68°C 7,5 minutes 
1 68°C 7 minutes 
- 4°C ∞ 
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Secondly, after the cycle is done, the parental non mutated DNA is digested with DpnI, 
leaving the PCR amplified DNA intact, therefore  only mutated plasmid DNA will be transformed into 
XL-gold ultracompetent bacteria, which offers a highest transformation efficiency and ideal for large 
plasmid DNA. As pcDNA 3.1 plasmids carry an antibiotic resistance genes to ampicillin, we used LB 
agar plates with Ampicilin (100µg/mL) resistance. Transformed bacteria were incubated for overnight 
at 37°C. To  proceed with the DNA extraction protocol, colonies had to be picked from the plates and 
incubated with 3mL LB Broth Medium and 100µg/μL Ampicillin, in a shaker at 37°C and 225rpm, 
overnight. The protocol used for DNA extraction is according to the one described at QIAprep® 
Miniprep Handbook. Briefly, collected overnight bacterial cultures were spin and pellets were first, 
ressuspended in Ressuspension Buffer (50mM Tris-HCL pH8.0; 10mM EDTA; 100μg/mL RNaseA), 
secondly lyzed with Lysis Buffer (200mM NaOH; 1%SDS), and finally neutralized with 
Neutralization Buffer (4,2M Gu-HCL; 0,9M potassium acetate; pH4,8). Then DNA is purified in 
QIAprep spin column, and eluted in Buffer EB (10mM Tris-HCL; pH 8,5) added to the column center. 
DNA concentrations and purity were measured using UV-Vis spectrophotometers NanoDrop™2000. 
Based on incident and transmitted light intensity, spectrophotometer produces an optical density that 
correlates with Lambert–Beer law and determines the unknown concentrations. 
 Then the plasmids were analyzed via Sanger sequencing, where 5µg DNA and 2,5µg primer 
were used. All sequences obtained were analyzed using the GATC viewer program, which allows 
checking the chromatogram and DNA sequence. After the analysis, one colony with the desired 
mutation was selected and further expanded and purified using the Genopure Plasmid Midi Kit 
(Roche), in order to obtain a highly quality purified plasmid DNA. Briefly, the selected colony is 
inoculated in a bacterial culture of 50ml and incubated overnight at 37°C at 225rpm. The bacterial 
culture is centrifuged and pellets are ressuspended in Suspension Buffer (complemented with 
lyophilized enzyme RNase A), lysed and then neutralized. DNA was purified and washed, within a 
column, and then eluted with Elution Buffer. At that point, DNA is precipitated with isopropanol and 
washed in ethanol 70%. Concentrations were measured using NanoDrop™2000, as described above. 
Cell Culture and cell lines  
The HeLa-CrispR/Cas9-PINK1 cell line (here within referred to as HeLa PINK1 KO) were 
previously described (Aerts et al., 2015). Briefly, these cells were generated using clustered regularly 
interspaced short palindromic repeats/Cas technology. A target sequence was selected from the first 
exon spanning the start codon of PINK1, cloned in pX330-U6-Chimeric-BB-CBh-hSpCas9 
(Addgene), and the plasmid was transfected in WT HeLa cells. PINK1 expression was analyzed, via 
Western Blot and clones in which PINK1 expression was absent were selected. These were subjected 
to MiSeq Next Generation sequencing analysis (Illumina) for the PINK1 gene sequence and the top 
five off-target regions in the HeLa genome for the clustered regularly interspaced short palindromic 
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repeats guide RNA. Product generated, on all chromosomal copies, were an 84-bp deletion spanning 
the start codon of PINK1. 
Other cell lines used were COS and HeLa WT. Cells were cultured at 37°C with 5% CO2 in 
DMEM/F12 medium containing 10% fetal bovine serum (Life technologies). All cell lines were 
ideally manipulated with approximately 80% confluence.  
Parkin expression and purification 
The procedure is described in Aerts et al., 2015. Briefly, BL 21 bacteria were transformed 
with pGEX-4T-1 expressing an N-terminal GST-tagged Ubl-domain of Parkin. Parkin expression was 
induced with 100μM IPTG, a reagent that induces protein expression where the gene is under the 
control of the lac operator; and cells were incubated at 37°C with 280rpm of agitation for 2hours. 
After a 15 minutes centrifugation, bacterial pellets were lyzed in 50mM Tris-HCl pH 7.5, 150mM 
NaCl, 1% Triton X-100, 2mM EDTA, 0.1% beta-mercaptoethanol, 0.2mM PMSF and 1mM 
benzamidine. GST-Ubl Parkin was purified using Glutathione Sepharose™ 4B (GE Healthcare), 
according to manufacturer’s instructions. Control samples were retained in every purification step, 
quality and purity was evaluated via western blot.  Briefly, this technique allows proteins separations 
based on molecular weight, by gel electrophoresis, producing a band for each protein. The proteins in 
the gel are then transferred to a nitrocellulose membrane, which is then incubated with antibodies to 
the protein of interest, and then develop (Mahmood & Yang, 2012). For Parkin membranes it was used 
for primary antibody rabbit anti-GST (1/1000; Sigma) and secondary antibody GARPO (1/10000; Bio-
Rad). 
Parkin recruitment 
The procedure was adapted from Aerts et al., 2015. HeLa cells were plated in a 24-well plate, 











HeLa WT HeLa PINK1 
KO 
Figure 3.2 - Exemplifying scheme of HeLa cell line plating 
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All the cell lines were transfected using FuGENE transfection reagent, agreeing to the 
manufacturer’s instructions. This transfection protocol uses a ratio transfection reagent to DNA of 3:1. 
HeLa cells were transfected with mParkin-GFP and pcDNA3.1-hPINK1 WT or corresponding PINK1 
mutants as described in table 3.3, and according to the manufacturer’s instructions.  
Twenty-four hours post transfection, cells were treated with 10μM CCCP for 3hours or, as 
control, the equivalent volume of DMSO. CCCP is an uncoupling agent that is used to induce 
mitochondrial membrane depolarization by increasing membrane permeability to H
+
). Cells were 
washed 3 times in PBS
+/+
 (100 ml 10x PBS
-/-
; 2M CaCl2; 1M MgCl2), fixed for 20 minutes in 4% 
formaldehyde in PBS
+/+
, washed 3 times in PBS
+/+
, permeabilized in 0,1% Triton X-100  in PBS
+/+
 for 
10 minutes, and washed 3times in PBS
+/+
 afterwards. Cells were blocked for 1 hour in Blocking Buffer 
(0,2% gelatin, 2% fetal bovine serum, 2% bovine serum albumin, 0.3% Triton X-100 in PBS
-/-
) and 
5% goat serum (Dako). Cells were stained using the mouse Turbo-GFP antibody (1/1000; Evrogen) 
and sheep Cytochrome c antibody (1/500; Sigma) for 2 hours. Cells were further washed 3 times with 
PBS
+/+
, and further incubated with secondary antibodies Alexa 488 donkey anti-rabbit and Alexa 568 
donkey anti-sheep (Life Technologies), in a 1/500 dilution. Images were acquired on a Zeiss LSM 710 
confocal microscope, using a 40x objective, and analyzed with Image J and Photoshop software’s.  
Table 3.3 - List of plasmids used to transfect HeLa cells 
Plasmids 
pCMV6 mParkin-GFP 
pMSCV hPINK1 FL WT 
pMSCV hPINK1 FL KI 
pMSCV hPINK1 FL G309D 
pMSCV hPINK1 FL L347P 
pMSCV hPINK1 FL E417G 
pMSCV hPINK1 FL H271Q 
pMSCV hPINK1 FL W437X 
 
 
 Human PINK1 purification and in vitro kinase assay 
The guidelines for this procedure were optimized and are described in Aerts et al., 2015. COS-
1 cells were transfected with the plasmids described in table 3.4, according to manufacturer’s 
instructions, using FuGENE transfection reagent (Promega). Forty-eight hours post transfections, cells 
were washed and harvest using a cell scrapper and collected in PBS. After a 10 minutes centrifugation 
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step, cells were lyzed in Lysis buffer (25mM Tris-HCl pH 7.5, 150mM NaCl, 5mM NaF, 1mM 
MgCl2, 1mM MnCl2, 0.5% Igepal-NP40 (Sigma), 50mg/L DNAse (Sigma), 50mg/L RNAse (Sigma), 
1mM DTT), with 20% protease inhibitor cocktail for mammalian cell and tissue extraction (Sigma), 
2X complete protease inhibitor (Roche), 4X PhosSTOP tablets (Roche) and homogenized using a 22-
G needle in 5 strokes. Lysates were centrifuged during 25 minutes at maximal rpm, and then incubated 
for 45 minutes at 4°C with FLAG-magnetic beads (Sigma). The unbound fraction was removed, and 
beads were washed 2 times with Lysis buffer and 3 times with kinase assay buffer (50mM Tris-HCl 
pH 7.5, 150mM NaCl, 10mM MgCl2, 3mM MnCl2 and 0.5mM DTT). 
The kinase assay was executed immediately after the binding step where purified hPINK1-
FLAG bound on the beads was incubated with 3,35μL of Parkin (2μg) , 10mM DTT and 100μM ATP 
containing 5μCi [-
32
P] ATP. Reactions were incubated for 1hour at 22°C.  
Samples were analyzed by SDS-PAGE followed by Western blotting. For this, samples were 
incubated for 10 minutes at 70°C with Sample Buffer (77.8mM Tris-HCl pH6.8; 44,4% (v/v) glycerol; 
4,4% LDS; 0,02% bromophenol blue and 4% β-mercaptoethanol). Samples were loaded on Mini-
PROTEAN 7.5% Tris-Glycine Gels, the electrophoresis separation occurred for approx. 1 hour in 
Running Buffer (25mM Tris-HCl pH 8.3, 190mM glycine, 0.1% SDS). After SDS-PAGE, samples 
were transferred onto a PVDF 0.45µm membrane in Transfer buffer (25mM Tris-HCl pH 8.3, 190mM 
glycine, 20% methanol) for 1 hour at 100V. After transfer, PVDF membrane was stored in an 
autoradiography cassette with an amplifying film. Incorporation of radiolabelled phosphor was assed 
via a storage phosphor screen and development on Typhoon (GE Healthcare Life Sciences). Image 
studio lite software was used for signal quantification. 
After radiolabelled phosphor quantification, the PVDF membranes were blocked for 1hour in 
5% milk in TBS-T (50 mM Tris-HCl pH 7.5; 150 mM NaCl, 0.1% Tween-20), and incubated with 
agitation in primary antibody mouse anti-Flag M2 (1/5000; Sigma) and rabbit anti-GST (1/5000; 
Sigma), overnight.  
Table 3.4 - Plasmids transfected on COS-1 cell line 
Plasmids 
pcDNA 3.1 hPINK1 ΔN WT 
pcDNA 3.1 hPINK1 ΔN KI 
pcDNA 3.1 hPINK1 ΔN G309D 
pcDNA 3.1 hPINK1 ΔN L347P 
pcDNA 3.1 hPINK1 ΔN E417G 
pcDNA 3.1 hPINK1 ΔN H271Q 
pcDNA 3.1 hPINK1 ΔN W437X 
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Statistical analysis 
Statistical significance between the different test conditions was analysed using GraphPad Prism 
5.03 software, through unpaired Student’s t-test (*: p<0,05; **; p<0,01; ***<0,001; ns: no significant). 
Data are shown as mean +/- standard errors of the mean (SEM), with 95% of confidence interval, in a 





4. Results and Discussion 
Parkin recruitment 
The mutations studied have been previously identified as altered in PD, as earlier described in 
Chapter 1 (Fig.4.1). Quite a few studies have reported PINK1 G309D, L347P, H271Q and W437X 
mutants behaviour relatively to Parkin recruitment. However there is some contradiction in these 
reports due to the use of different experimental conditions (such as concentration or exposure time to 









In order to verify the impact of hPINK1 clinical mutants on Parkin recruitment, we transfected 
HeLa WT and HeLa-PINK1-KO cells with PINK1 constructs and with a GFP-tagged Parkin construct. 
Dual staining was performed in all cell lines studied. We confirmed that in basal conditions, Parkin is 
predominately located in the cytosol as expected (Fig.4.2B and Fig.4.2H), and does not colocalize 
with mitochondria (Fig.4.2C and  Fig.4.2I). Although, when HeLa WT cells were treated with CCCP, 
a loss of mitochondrial network is observed when staining for a mitochondrial resident protein 
Cytochrome c and a perinuclear clustering of mitochondria is observed (Fig.4.2.D), and more 
interestingly Parkin is recruited to the mitochondria (Fig.4.2F). This does not happen in HeLa PINK1 
KO cells treated with CCCP where, in the absence PINK1, Parkin is not recruited to mitochondria 
(Fig.4.2L). This observation is in agreement with previous studies (Narendra et al., 2010) that show 
that Parkin recruitment to depolarized mitochondria requires the presence of PINK1. 
 
Figure 4.1 – Schematic representation of PINK1 
PINK1 is a 581 amino acid protein which localizes to the mitochondria via 
an N-terminal mitochondrial targeting sequence (black arrow) and contains 
a catalytic serine/threonine kinase domain. PINK1 clinical mutations (Black 
arrow head) and a residue responsible for kinase activity (blue arrow head) 
of localized within the kinase domain of PINK1. Adapted from (Bonifati, 


































































Figure 4.2 – Parkin recruitment to depolarized mitochondria in HeLa WT and HeLa-PINK1-KO. Cells were 
transfected with mParkin-GFP and treated with DMSO or 10μΜ CCCP in serum for 3h. Mitochondria were 
immunostained for Cyto. C. The images in column on the right are merged images of the middle (Parkin staining) 
and left-hand (Mitochondria staining) columns. Scale bar=10μM 
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 Additionally, to further confirm that Parkin recruitment is dependent not only on the presence 
of the PINK1 protein but also requires an active form of PINK1, we transfected HeLa WT and HeLa-
PINK1-KO cells with a kinase inactive mutant form of PINK1, the hPINK1 KI, and Parkin 
recruitment was evaluated. At present, there is not a known stoichiometry between PINK1 levels and 
Parkin recruitment (Seirafi et al., 2015), therefore, in order to quantify the percentage of cells where 
Parkin recruitment is occurring we quantified cells that presented staining for Cytochrome c and 
Parkin simultaneously. The quantified data for cells treated with DMSO and CCCP are represented in 










In DMSO conditions (Fig. 4.3A), Parkin recruitment shows no significant alterations between 
the different cell lines analysed. This is due to the fact that mitochondria are healthy with no defects at 
the level of mitochondrial membrane potential (Δm). 
When loss of Δm induced by CCCP treatment leads to a pool of damaged mitochondria 
represented by a loss in mitochondrial network and the formation of fragmented mitochondria (Fig. 
4.3B), there is a complete different response from Parkin which is dependent on the presence of 
PINK1. In HeLa WT cells transfected with PINK1 WT and treated with CCCP, we did not observe a 
difference between transfected and non-transfected cells. On the other hand, Parkin recruitment is 
significantly decreased in the presence of hPINK1-KI (Fig.4.3.B). Parkin recruitment can be recovered 
in Hela-PINK1-KO cells by expressing PINK1 WT (Fig.4.4F),  where 63,78% of recruitment is 
observed when compared to hPINK1 WT; but recruitment is not restored with PINK1 KI (Fig.4.3B; 
Fig4.4L), indicating that PINK1 has a crucial role in Parkin recruitment to mitochondria and cooperate 
functionally to clear damaged mitochondria via mitophagy. 
A B 
Figure 4.3 – Quantification of Parkin recruitment to mitochondria. A. Parkin recruitment in HeLa WT and Hela 
PINK1 KO cell lines, non-transfected, and transfected with hPINK1 WT and KI, in DMSO conditions; #=Cell line 
not transfected. B. Parkin recruitment in HeLa WT and HeLa PINK1 KO cell lines, non-transfected, and transfected 
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Figure 4.5 - Parkin recruitment to depolarized mitochondria in HeLa-PINK1-KO. HeLa-PINK1-KO cells 
were cotransfected with mParkin-GFP and pcDNA 3.1 .ΔN PINK1 WT or pcDNA 3.1 .ΔN PINK1 KI, and treated 
with DMSO or 10μM CCCP in serum for 3h. Mitochondria were immunostained for Cyto. C. The images in 
column on the right are merged images of the middle (Parkin staining) and left-hand (Mitochondria staining) 




In order to elucidate the impact of clinical PINK1 mutants on Parkin recruitment to 
mitochondria, we transfected HeLa-PINK1-KO with mParkin-GFP and hPINK1 clinical mutants, and 
investigated Parkin recruitment in the presence of CCCP treatment. Immunofluorescent images and 
consequent quantification was obtained for all studied mutants. 
 
Interestingly, in healthy mitochondria (DMSO treatment) the PINK1 clinical mutants induced 
a subtle, albeit significant, increase in Parkin recruitment when compared to hPINK1 WT (Fig.4.5C; 
Fig.4.6C; Fig.4.6I; Fig.4.7C). However, the mutant hPINK1 L347P does not present a loss of 
mitochondrial network and Parkin maintains a preferential cytosolic localization (Fig.4.5L). 



























































Figure 4.5 - Parkin recruitment to depolarized mitochondria in PINK1 W437X and L347P mutants. HeLa-
PINK1-KO cells were cotransfected with mParkin-GFP and pcDNA 3.1 .ΔN PINK1 W437X or pcDNA 3.1 .ΔN 
PINK1 L347P ,and treated with DMSO or 10μM CCCP in serum for 3h. Mitochondria were immunostained for 
Cyto. C. The images in column on the right are merged images of the middle (Parkin staining) and left-hand 














































Figure 4.6 - Parkin recruitment to depolarized mitochondria in PINK1 H271Q and G309D mutants. HeLa-
PINK1-KO cells were cotransfected with mParkin-GFP and pcDNA 3.1 .ΔN PINK1 H271Q or pcDNA 3.1 .ΔN 
PINK1 G309D, and treated with DMSO or 10μM CCCP in serum for 3h. Mitochondria were immunostained for 
Cyto. C. The images in column on the right are merged images of the middle (Parkin staining) and left-hand 
(Mitochondria staining) columns. Scale bar=10μM. 
G H I 
J K L 
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In order to mimic depolarized mitochondria, cells were treated with CCCP. In this case all 
mutants showed Parkin recruitment and presented total or partial colocalization with the mitochondrial 
marker Cytochrome c (Fig.4.5D-F; Fig.4.5J-L; Fig.4.6D-F; Fig.4.6J-L; Fig.4.7D-F). However, the 
clinical mutants are not able to restore Parkin recruitment to levels comparable with hPINK1 WT, 
indicating that these mutations that occur in hPINK1 lead to the expression of a hampered active form 
















Transfected cells were scored for presence of Parkin-GFP (Figure 4.9) and further quantified 
for Parkin recruitment (Fig.4.8). All clinical mutants presented similar percentage of Parkin-GFP 
transfection, indicating that observed results within clinical mutants is not due to lower Parkin-GFP 
transfection efficiency. In cells treated with DMSO, PINK1 clinical mutants where able to 
significantly recruit Parkin when compared to non-transfected HeLa-hPINK1-KO cells, with the 
exception of PINK1 L347P. These results show that mitophagy can occur in healthy mitochondria, and 
that mitochondria turnover also occurs at basal levels. Nevertheless, this phenotype is massively 
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Figure 4.7 - Parkin recruitment to depolarized mitochondria in PINK1 E417G mutant. 
HeLa-PINK1-KO cells were cotransfected with mParkin-GFP and pcDNA 3.1 .ΔN PINK1 
E417G, and treated with DMSO or 10μM CCCP in serum for 3h. Mitochondria were 
immunostained for Cyto. C. The images in column on the right are merged images of the middle 














Figure 4.8 – Quantification of Parkin recruitment to mitochondria in PINK1 mutants. A. Parkin recruitment in 
Hela PINK1 KO cells, non-transfected, and transfected with hPINK1 WT, KI and mutants, in DMSO conditions; #: 
Cell line not transfected. B. Parkin recruitment in Hela PINK1 KO cell line, non-transfected, and transfected with 
hPINK1 WT, KI and mutants, in CCCP conditions; #: Cell line not transfected. 
A B 
Figure 4.9 - Cells transfected with mParkin. A. Hela WT and HeLa PINK1 KO cells transfected with Parkin (%), in 
DMSO conditions. There is a significant difference between Hela WT non-transfected (#) and HeLa WT KO non-
transfected (#). B. Hela WT and HeLa PINK1 KO cells transfected with Parkin (%), in CCCP conditions. There is a 
significant difference between Hela WT non-transfected (#) and all samples, except HeLa WT transfected with WT 
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Neuronal cells expressing the PINK1 W437X mutant show a significant increase in 
mitochondria size and loss of mitochondria cristae, as well as loss of Δm and decrease in ATP 
production. This mutant exacerbates the accumulation of α-synuclein by mitochondrial calcium flux 
dysregulation (Marongiu et al., 2009). While Fallaize and co-workers have shown that PINK1 W437X 
abolishes the ability of PINK1 to translocate to OMM following CCCP treatment (Fallaize et al., 
2015), another study has shown that the expression of PINK1 W437X results in more pronounced 
initial mitochondrial localization, even in the absence of mitochondrial damage (Geisler et al., 2010). 
Our results go in line with reports from Geisler and co-workers, where even without CCCP treatment 
we observed a residual Parkin recruitment (Fig.4.5C and Fig.4.8A). The same happens with PINK1 
H271Q (Fig.4.6C), G309D (Fig.4.6I) and E417G (Fig.4.7C) clinical mutants, where a significant 
recruitment of Parkin occurs in Hela-hPINK1-KO non-transfected cells (Fig.4.8A). 
Previous studies have shown that the PD linked mutation L347P has no effect on PINK1 sub-
mitochondrial localization in either healthy or CCCP-depolarized mitochondria (Fallaize et al., 2015). 
Narendra and co-workers have reported that PINK1 mutant L347P is unstable and fails to reconstitute 
Parkin recruitment to depolarized mitochondria, as well as H271Q (Narendra et al., 2010). Taking into 
account our results, we could postulate that the kinase activity of this protein may not be required for 
mitochondrial depolarization-induced PINK1 OMM translocations. On the other hand, for PINK1 
H271Q we observed Parkin recruitment for both DMSO and CCCP conditions. (Fig.4.6.A-F) 
(Fig.4.8A and Fig.4.8B). 
Reports have shown that PINK1 G309D mutation does not alter the production of full length 
WT PINK1, but abrogates the protective function of PINK1 (Valente et al., 2004). The PINK1 G309D 
mutant restores the mitochondrial localization and Parkin activation after CCCP treatment (Matsuda et 
al., 2010). Also G309D, can partially reconstituted Parkin recruitment (Narendra et al., 2010). Our 
results are in agreement with these findings. 
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In vitro PINK1 phosphorylation assay 
Parkin expression and purification 
Recombinant GST-Ubl Parkin protein was expressed using a bacterial protein expression 
system. Ubl-Parkin protein expression was induced using IPTG and further purified from the bacterial 
lysate by performing a gluthathione chromatography against the GST-tag present in the recombinant 
protein. In order to evaluate the efficiency of purification of Ubl-Parkin, aliquots from all relevant 
steps from the purification where analyzed by SDS-PAGE followed either by Coomassie staining or 
by Western Blot analysis: lysate, the supernatant obtained after bacterial lysis; unbound, the fraction of 
protein that wasn’t retained at the column; and 3 elutes, the elution fraction of our protein of interest. 
Coomassie dye binds to proteins through ionic interactions between dye sulfonic acid groups and 
positive protein amine groups as well as through Van der Waals attractions. Dye that is not bound to 
protein diffuses out of the gel during the destain steps. Then the proteins are detected as blue bands on 
a clear background (Fig.4.10A). 
Ubl Parkin enrichment was assessed by Western blotting where Parkin protein was probed 
using the rabbit anti-GST antibody, which will specifically bind to the GST-tag present in our protein 
of interest. As a secondary antibody, we used the goat anti-rabbit IgG (H+L) fused with horseradish 
peroxidase. This enzymatic reporter will interact with the luminol-based substrate producing a 










The analysis of the Coomassie stained gel (Fig.4.10A) reveals an efficient purification of 
GST-Ubl-Parkin, as the major band present in the lysate that corresponds to the predicted molecular 
weight of GST-Ubl-Parkin (36kDa) is clearly enriched in the Elute fraction 2 and 3 (10µg Lysate and 
2µg Elute 2 were loaded on the SDS-PAGE). Additionally, the absence of this band in the unbound 



































































 A B 
Figure 4.6 – Ubl-Parkin expression and purification. A. Coomassie staining of GST Ubl Parkin (red 
arrow). B. Membrane obtained from Western Blot of GST Parkin (red arrow). 
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The protein concentration was measured using the Bradford Protein Assay (Bio-Rad). Briefly, 
this is method for protein quantification based on the dye Coomassie Brilliant Blue G-250 binding to 
proteins. The binding will induce pH changes; predominantly dye is in a protonated cationic form 
(red); but when dye binds to protein, it is converted to an anionic form (blue). This protein-dye 
interaction in a blue form is detected at the absorbance wavelength of 595nm. In table 4.1 is 
represented the estimated molecular weight of protein bands detected in our Coomassie stained gel, as 
well as the concentration of each fraction analysed (20μg). 
Table 4.1 - Results for GST-Ubl Parkin Quantification;μL, were the quantity of each sample pipetted for 96-well plate; μg 






 Considering the three elutes, it was decided to proceed with Elute 2, as either in Coomassie or 
Western blot results this elution fraction present the highest amount of Ubl-Parkin.. 
hPink expression and purification 
PINK1 is a delicate protein to work with, as it is highly instable, and several steps are required 
in order to obtain a functionally purified form of PINK1 (Hertz et al., 2013; Aerts et al., 2016). 
Diverse protein tags were tested in order to obtained a more effective purification and expression of 
this protein, it was concluded that the tandem affinity purification tag 3xFLAG-Streptavidin was the 
most efficient (Aerts et al., 2016). Briefly, this expression and purification procedure requires and 
overall short time of manipulation as PINK1 has a short half-life of approximately five hours (Choo et 
al., 2012); the kinase assays temperature shifts from 30°C to 22°C; and the reducing agent DTT was 
added, since it improves phosphorylation detection. 
Transient expression of the PINK1 clinical mutants was checked by Western blotting against 
the FLAG tag present in these mutants (Fig.4.11). Typically, immunoblotting for PINK1 reveal not 
only FL PINK1 (blue arrow), but also its three processed forms: first (orange arrow) resulting from 
MPP cleavage (ΔMTS); secondly (red arrow), resulting from PARL cleavage (ΔN1); and ΔN2 for 








μL μg sample/well 
Lysate 35,363575 10 7,87 
Elute 1 34,313031 2 3,35 
Elute 2 35,900845 2 3,35 











Analysis of the results obtained from the in vitro phosphorylation assay clearly show that FL 
PINK1 phosphorylates the Ubl domain of Parkin (Fig.4.12B), however phosphorylation of PINK1 



















WT KI G309D L347P E417G H271Q W437X 
P32: FL PINK1 
WT KI G309D L347P E417G H271Q W437X 
WB: FL PINK1 
A 
WT KI G309D L347P E417G H271Q W437X 
P32: Ubl Parkin 
WT KI G309D L347P E417G H271Q W437X 
WB: Ubl Parkin 
B 
Figure 4.8 – In vitro assay with FL PINK1. A. Phosphorylation assay using [ϒ-32P]-ATP performed with 
purified FL PINK1 (red arrow). Although WB shows FL PINK1 expression, the autoradiogram does not 
indicate FL PINK1 phosphorylation, neither in the WT, KI or any mutant. B. Phosphorylation assay using [ϒ-
32P]-ATP performed with purified FL PINK1 and Ubl Parkin. Autoradiogram shows that Ubl Parkin (green 





































Figure 4.7 – COS Tranfection. COS Transfected with PINK1 WT, KI 
and 5 studied mutants, expressing different hPINK1 forms. Blue arrow 
represents FL PINK1; Orange arrow represents ΔMTS form; Red arrow 
for ΔN1 form; and Green arrow for ΔN2 
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 But when the assay was performed employing the PINK1 form lacking the N-terminal region 
(ΔN PINK1), both substrate phosphorylation (Fig.4.13B) and (auto)phosphorylation (Fig.4.13A) was 
detected. These results suggest that N-terminal of hPINK1 may play a role in PINK1 
(auto)phosphorylation. Still Parkin phosphorylation appears not affected in either of the cases.  
Previous studies from this laboratory have reported (Aerts et al., 2015) that lack of PINK1 
(auto)phosphorylation by FL PINK1 is not due to a prior phosphorylation and occupancy of sites sides 
by non-radioactive phosphates. They conducted studies using lambda protein phosphatase (LPP) to 



















The protein bands obtained in the autoradiogram and in the Western blot were quantified using 
Image Studio Lite software, and the obtained data collected is summarized in Fig.4.14.  
WT KI G309D L347P E417G H271Q W437X 
P32: ΔN PINK1 
WB: ΔN PINK1 
WT KI G309D L347P E417G H271Q W437X 
A 
WB: Ubl Parkin 
W437X H271Q E417G L347P G309D WT KI 
W437X H271Q E417G L347P G309D WT KI 
P32: Ubl Parkin 
B 
Figure 4.9 - In vitro assay with ΔN PINK1. A. Phosphorylation assay using [ϒ-32P]-ATP performed with purified 
ΔN PINK1 (red arrows). PINK1 mutants seem to follow a phosphorylation level near to PINK1 KI. B. 
Phosphorylation assay using [ϒ-32P]-ATP performed with purified ΔN PINK1 and Ubl Parkin. Autoradiogram 
shows that Ubl Parkin (green arrows) is phosphorylated by ΔN PINK1, with PINK1 G309D and PINK1 W437X 
presenting phosphorylation levels close to PINK1 WT (n = 3 independent experiments). 
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For PINK1 (auto)phosphorylation (Fig.4.14A), we report that all clinical mutants present a 
kinase activity comparable to the kinase inactive form of PINK1, with the exception of PINK1 G309D 
mutant where an activity of 46,93% was observed. 
  For phosphorylation of the substrate Parkin (Fig.4.14B), only the PINK1 W437X mutant 
presented a phosphorylation pattern comparable to PINK1 WT (61,67%). All the other PINK1 mutants 
(G309D 47,25%; L347P 38,02%; H271Q 26,66% and E417G 20,44%) presented a phosphorylation 
intensity of Parkin near to the levels detected for PINK1 KI. In conclusion, the PINK1 clinical mutants 
have a decreased ability to phosphorylate the substrate Parkin as well as to (auto)phosphorylating 
PINK1. 
In sum, PINK1 L347P, PINK1 E417G and PINK1 H271Q show low phosphorylation levels, 
for both PINK1 and Parkin. Indicating that, the referred alterations, in the kinase domain affect PINK1 
kinase activity. The PINK1 G309D mutant shows a defective phosphorylation towards 
(auto)phosphorylation of PINK1; the mean per se is not differing in large percentage of PINK1 KI or 
the other mutants, suggesting that the difference may be due to a higher experimental variation 
reflected by the calculated SEM value.  
PINK1 W437X behaves the other way around: for PINK1 (auto)phosphorylation this mutant 
presents levels comparable to the ones obtained for PINK1 KI, but for Parkin phosphorylation this 
mutant seems not to be affected. Ideally additional experiments should be performed to confirm this 










As for Parkin recruitment to mitochondria, it has previously been described that some 
mutations in PINK1 could dysregulate PINK1 (auto)phosphotylation. 
A B 
Figure 4.10 - Quantification of in vitro [ϒ-32P]-ATP phosphorylation. A. Phosphorylation by purified ΔN 
PINK1. Besides PINK1 G309D, all other PINK1 mutants show significant difference to the WT, proximate to 
PINK1 KI levels. B. Phosphorylation by purified ΔN PINK1 with Ubl Parkin. All PINK1 mutants show 
phosphorylation levels next to PINK1 KI levels. 
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Beilina et al. (2005) reported that residues G309 and L347 are not predicted to be within the 
active site of the kinase domain but in areas important for protein folding. The G309 residue is 
predicted to be near the ATP binding site, and residue L347 in the cyclin binding surface (cyclin-
dependent protein kinases). Therefore, a G309D point mutation is unlikely to grossly destabilize the 
fold but could interfere electrostatically with ATP binding or hydrolysis, justifying PINK1 G309D 
incompetence to phosphorylate Parkin.  Also the fact that PINK1 L347P has a deficient enzymatic 
activity is probably explained by impaired cyclin binding surface, which could lead to the 
phosphorylation alterations that we report. Indeed the L347P residue is known to disrupt PINK1 
kinase activity (Pridgeon et al., 2007), and it was reported to be unstable, because it does not bind to 
the Hsp90-Dcd37 chaperone complex (Song et al., 2013).  
Catalytically active mutants orthologues of PINK1 have been studied and revealed that 
residuesH271Q, E417G and L347P appear to virtually abolishes or ablates kinase activity (Woodroof 
et al., 2011). 
For PINK1 W437X mutant, it has previously been reported that this mutant presents increased 
kinase activity towards substrates (Sim et al., 2006) and also for PINK1 (auto)phosphorylation 
(Silvestri et al., 2005) when compared to a kinase inactive form. But these assays were performed with 
different forms of full length PINK1 and with different in vitro assay settings, which may lead to 
discrepancy when comparing results. For example, delaying PINK1 activity measurement strongly 
reduces phosphorylation signal, once an unclear rapid loss of PINK1 kinase activity is observed. A 
lower incubation temperature improves results, and using strong reducing conditions PINK1 catalytic 
activity is stimulated (Aerts et al., 2016). 
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5. General conclusion and future work 
 
Parkinson’s disease is the second most common neurodegenerative disorder, thus clarification 
of its pathogenic mechanism and the development of new diagnostic approaches and effective 
therapeutics are eagerly awaited. In the past few years a connection between this disease and 
mitochondria has been strengthened. Additionally, the autophagic removal of damaged mitochondria 
(mitophagy) is of crucial importance in postmitotic cells such as neurons, as the lack of cell division 
reduces the clearance of dysfunctional damaged mitochondria, resulting in energy deficiency and 
increasing oxidative stress. These events will further damage mitochondria and other macromolecules, 
causing an ever-increasing spiral of damage that eventually leads to cell death. 
We report that Parkin recruitment occurs in PINK1 mutants, however we were not able to 
detect a significant phosphorylation levels for the substrates PINK1 or Parkin. Thus, our results 
suggest that the presence of PINK1 is essential for Parkin recruitment to occur, however PINK1s’ 
kinase activity is not required for this process. Consequently, although Parkin is recruited to the 
mitochondria, mitochondria present a donut-shaped morphology typically observed when mitophagy 
is initiated (Haddad et al., 2013). As PINK1 is not able to phosphorylate Parkin and therefore 
mitophagy does not proceed, accumulation of these donut-shaped mitochondria occurs in the presence 
of our PINK1 clinical mutants. In order to further validate this hypothesis, a time-course spanning up 
to 72 hours should be performed for the CCCP treatment. This experiment will determine if inhibition 
of the PINK1/Parkin regulated mitophagy pathways occurs. 
Recently (Zhang et al., 2016) reported that in mammalian cells, BNIP3 inactivation promotes 
PINK1 proteolytic processing and promotes PINK1/Parkin regulated mitophagy, once this protein can 
recruit Parkin to mitochondria independently of PINK1. As BNIP3 interacts with LC3 directly 
promoting mitophagy, this would suggest that PINK1 activity is not obligatory for this pathway.  We 
think that this rather recent findings may explain why the lack of PINK1 activity in these mutants is 
not interfering with Parkin recruitment. BNIP3 may be compensating for the PINK1 deficiency and 
restoring mitophagy. To address this issue, the gain- and loss-of-function of BNIP3 should be assessed 
within the mitophagy pathway, and also expression levels of BNIP3 should be determined in a PINK1 
null background. Further, it would be interesting to investigate how BNIP3 is performing in PINK1 
mutants. 
Additionally, another interesting aspect that could explain our results concerning the fact that 
Parkin recruitment is still occurring in the presence of PINK1 clinical mutants could be that there is an 
increase in PGC-1α mediated mitochondria biogenesis (Henchcliffe & Beal, 2008). To tackle this 
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hypothesis we would initially need to determine if an increase in the PGC-1α signaling pathways is 
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Material and Equipment 
Mutants Construction: 
Mutant Strand Synthesis Reaction 
 PCR tube 
 QuikChange II XL Site-Directed Mutagenesis Kit reagents:  
o 10x reaction buffer; 
o dNTP mix; 
o QuikSolution reagent; 
 Double distilled water (ddH20); 
 PfuUltra HF DNA polymerase (2.5U/μL). 
For the control reactions: 
 pWhitescript 4.5-kb control plasmid (5ng/μL) 
 Nucleotide control primer #1 [34-mer(100ng/μL) 
 Nucleotide control primer #2 [34-mer(100ng/μL) 
 
For the samples: 
 pcDNA 3.1 hPINK1 WT ΔN 
 Primers refered in table 2.1 “Mutagenesis Primers” section 
 
Dpn I digestion 
 Products of amplification 
 1μL DpnI restriction enzyme (10U/μL) 
 
Transformation of XL-Gold Ultracompetent cells 
 1,5mL eppendorfs 
 XL-gold ultracompetent  
 β-mercaptoethanol (β-ME) mix 
 Samples (DpnI treated DNA) 
 Thermomixer 
 SOC Medium  





Cell Culture – cells maintenance  
 Water bath  
 DMEM (Thermo Fisher Scientific) +10%FBS (Thermo Fisher Scientific) 
 DPBS (Thermo Fisher Scientific) 
 Trypsin-EDTA (0,05%) (Thermo Fisher Scientific) 
 Flux 
 Incubator  
 Micropipettes (1mL, 200μL,100μL, 20μL, 10μL and 2μL) 
 Micropipette tips 
 Pipettes (Thermo Fisher Scientific) 
 Automatic pipettor 
 T75 flasks (Nunc) 
 T175 flasks (Nunc) 
 
Cell Culture – cells plating 
 24 well plate (Corning) 
 T175 flasks (Nunc) 
 Water bath 
 DMEM (Thermo Fisher Scientific) +10%FBS (Thermo Fisher Scientific) 
 DPBS (Thermo Fisher Scientific) 
 Trypsin-EDTA (0,05%) (Thermo Fisher Scientific) 
 Falcons 15mL (Frilabo) 
 Pipettes (Thermo Fisher Scientific) 
 Pipette tips 
 Eppendorfs 1,5mL 
 Tweezer 
 Coverslip 13mm 
 Incubator 
 
Cell Culture – cells transfection 
 Water bath (37°C)  
 DMEM (Thermo Fisher Scientific) +10%FBS (Thermo Fisher Scientific) 
 DMEM (serum free) (Thermo Fisher Scientific) 
 1,5 mL Eppendorf 
 FuGENE 6 transfection reagent 
 Plasmid DNA (represented in table 1) 
 Falcons 15mL 
 Micropipettes 




 LB Broth Medium  
 Ampicillin 100μg/mL 
 PS tube sterile 
 Micropipette tip 
 Petri Dish 
 Shaker at 37°C and 225rpm, overnight. 
 Overnight bacterial cultures 
 2mL and 1,5mL eppendorf 
 Centrifuge 
 Nanodrop 
 QIAprep Spin Miniprep Kit reagents: 
o Buffer P1 
o Buffer P2 
o Buffer N3 
o QIAprep spin column 
o Buffer PE 
o Buffer EB 
 
Sequencing 
 1,5mL eppendorf tubes 
 Provided barcodes 
 Primers (10μM), described at table 2.1. 
 ddH2O water 
 
Midi-preps 
 Bacterial culture 
 Genopure Plasmid Midi Kit (Roche) 
o RNase A (lyophilized enzyme) 
o Suspension Buffer 
o Lysis Buffer 
o Neutralization Buffer 
o Equilibration Buffer 
o Wash Buffer 
o Elution Buffer 
o NucleoBond AX 100 Columns 
o Folded filters 
o Sealing rings 
 Nanodrop 
 Pipettes: 2mL, 5mL, 10mL, 25mL (Fisher Scientific)   




 Cell lines: HeLa WT and HeLa-PINK1-KO 
 24 well plate 
 FuGENE transfection reagent (Promega) 
 DMSO (Sigma-Aldrich) 
 0,1M CCCP (Sigma-Aldrich) 
 PBS+/+(100 ml 10x PBS-/-; 2M CaCl2; 1M MgCl2) 
 Formaldehyde (Electron Microscopy Sciences) 
 Triton-X100 (Sigma-Aldrich) 
 Coverslips 13mm  
 Blocking Buffer (0,2% gelatin, 2% fetal bovine serum, 2% bovine serum albumin, 0.3% 
Triton X-100 in PBS
-/-
) 
 Goat serum (Dako) 
 Primary antibodies: 
o mouse Turbo GFP (Evrogen) 
o sheep Cytochrome c (Sigma) 
 PBS-/- (1370 mM Sodium chloride, 27 mM Potassium chloride, 81 mM Disodium hydrogen 
phosphate, 14.7 mM Potassium dihydrogen phosphate, 9.01 mM Calcium chloride, 4.92 mM 
Magnesium chloride) 
 Secondary antibodies:  
o Alexa 488 donkey anti-rabbit 
o Alexa 568 donkey anti-sheep 
 Mowiol 
 Nail polish 
 Microscope slide 
 
Parkin purification 
 BL21 bacteria 
 IPTG (Biochemica) 
 Lysis Buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 1% Triton X-100, 2mM EDTA, 0.1% 
beta-mercaptoethanol, 0.2mM PMSF and 1mM benzamidine) 
 Glutathione Sepharose™ 4B (GE Healthcare) 
 Running Buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3, H2O) 
 Transfer Buffer (10x Tris/glycine) 
 Electrophoresis and Trans-Blot® Cell systems: 
o Tetra Electrode Assembly; 
o Buffer Tank and Lid; 
o Gel Holder Cassette; 
o Thick Blot Filter Paper; 
o Foam Pads; 
o Trans-Blot Central Core. 
 Clarity™ and Clarity Max™ Western ECL Blotting Substrates (Bio-Rad) 
 Dry Milk (Nestlé) 
 TBS-T (1x TBS; 0,1% Tween) 
 Primary antibody: 
o  α-GST (1/5000; Sigma) 
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 Secondary antibody: 
o GARPO (1/10000; Bio-Rad) 
 Nitrocellulose membranes (GE Healthcare) 
 Precision Plus Protein Dual Color Standards (Bio-Rad) 
 4x Laemmli Sample Buffer (Bio-Rad) 
 Mini-Protean gels (Bio-Rad) 
 4% β-mercaptoethanol (Bio-Rad) 
 
Human PINK1 purification and in vitro kinase assay 
 Cell line: COS  
 Plasmids (described in table 2) 
 FuGENE transfection reagent (Promega) 
 DPBS 
 Lysis Buffer (25mM Tris-HCl pH 7.5, 150mM NaCl, 5mM NaF, 1mM MgCl2, 1mM MnCl2, 
0.5% Igepal-NP40 (Sigma), 50mg/L DNAse (Sigma), 50mg/L RNAse (Sigma), 1mM DTT), 
with 20% protease inhibitor cocktail for mammalian cell and tissue extraction (Sigma), 
Complete protease inhibitor (Roche), PhosSTOP tablets (Roche) 
 22-G needle 
 Centrifuge 
 FLAG-magnetic beads (Sigma) 
 Kinase assay buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 10mM MgCl2, 3mM MnCl2 and 
0.5mM DTT) 
 Parkin purified (obtained from Parkin purification protocol) 
 ATP containing 5μCi [ϒ-32P] ATP 
 Thermomixer 
 Mini-Protean gels (Bio-Rad) 
 4% β-mercaptoethanol (Bio-Rad) 
 4x Laemmli Sample Buffer (Bio-Rad) 
 PVDF membrane (GE Healthcare Life Sciences) 
 Precision Plus Protein Dual Color Standards (Bio-Rad) 
 P32 cassette 
 Typhoon 
 Dry Milk (Nestlé) 
 TBS-T (1x TBS; 0,1% Tween) 
 Primary antibody: 
o Mouse anti-Flag M2 (1/5000; Sigma) 
o α-GST (1/5000; Sigma) 
 Secondary antibody: 
o GARPO (1/10000; Bio-Rad) 
o GAMPO (1/10000; Bio-Rad) 
 Running Buffer (25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3, H2O) 
 Transfer Buffer (10x Tris/glycine) 
 Electrophoresis and Trans-Blot® Cell systems: 
o Tetra Electrode Assembly; 
o Buffer Tank and Lid; 
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o Gel Holder Cassette; 
o Thick Blot Filter Paper; 
o Foam Pads; 
o Trans-Blot Central Core. 
 Clarity™ and Clarity Max™ Western ECL Blotting Substrates (Bio-Rad) 
 
 
